Hetero-radionuclidic-phosphonate framework as a novel agent for pain palliation and PET imaging of metastatic bone

JOINT EVENT: 4^th International Conference and Exhibition on Medical Physics and Biophysics & 2^nd International Conference on Nuclear Medicine & Radiation Therapy

July 27-28, 2017 Rome, Italy

Simindokht Shirvani-Arani and Ali Bahrami Samani

Nuclear Science and Technology Research Institute, Iran

Posters & Accepted Abstracts: J Nucl Med Radiat Ther

Abstract :

Many radionuclides have been applied in preparation of DOTMP-containing Radiopharmaceuticals for treatment of bone metastases. It is vitally important to prepare a formula that makes PET imaging and an effective �²-therapy possible, in addition to a reduced molar ratio of bone-seeking agent to the radionuclide. Here MOF concept is contributed to the preparation of a novel theranostic bone-seeking agent with different sizes composed of Cu-64, Y-90, and DOTMP for treatment of bone metastases. The products were characterized (IR, elemental analysis: CHN, ICM-MS, PIXE) and quality-controlled (RTLC). The stability and in vitro hydroxyapatite binding were checked up to one week at 37áµ�C in human serum. Radio-MOF crystals and colloidal radio-MOF particles obtained by varying the synthesizing conditions (including pH and temperature), showed similar IR patterns and similar elemental analysis results. The chemical formula was [1Y-1Cu-1DOTMP] for both. The final product was synthesized at pH=8, stirring at room temperature using carrier free Y-90 and Cu-64 and DOTMP (yield > 99%, RTLC). In vitro binding experiments showed acceptable bone-seeking affinity of the prepared formula even after one week of storage in human serum at 370C. The in vivo bone-accumulation investigation of the formula also confirmed the results. Importantly, this is the first study of the usage of MOF concept to provide a high payload of radionuclide for theranostic treatment of bone metastases. The biodistribution studies in mice and PET imaging are planned for future studies. The possibility of �²-therapeutic (Y-90) and PET imaging (Cu-64) administrating one highly stable radio-MOF agent is presented.

Biography :

Email: sdshirvani@gmail.com